Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer Europe OTC Drugs

Third Class Of Drugs Back In The News With Proposed UK Statin Switch

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

J&J/Merck's application to make Zocor available in the UK without a prescription may revive debate in the U.S. regarding creation of a third class of drugs

You may also be interested in...



Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind

GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market

Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind

GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market

Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind

GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market

Table

View full table

Related Content

HBW Insight
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer Europe OTC Drugs
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS096203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By